Startup profile · funding coverage
Probably Genetic funding, valuation and investors
Patient-identification and rare-disease data platform connecting testing pathways with institutional research needs.
Keep track of Probably Genetic
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$12M · October 14, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$12M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Lead: Threshold Ventures
Other: Y Combinator , Other unnamed existing investors
Overview
Probably Genetic provides patient-identification and genetic-testing pathways and offers a data platform to institutional partners. Fierce Healthcare reported a $12M Series A led by Threshold Ventures with Y Combinator and other existing investors on October 14, 2026, including CEO and lead-investor comments. A separate earlier research award is not included in that round. Valuation and allocations were not disclosed.
Why Probably Genetic is interesting
The investment case depends on research-ready data quality, patient-access economics and repeat institutional use rather than profile counts alone.
Product & use cases
The company describes physician-ordered testing through sponsored and insurance-billed programs and an institutional partner offering for patient identification. Funding is not proof of diagnostic performance, a validated biological target or a successful therapy.
Funding history (newest first)
Series A
2026-10-14 $12M- Threshold Ventures (lead)
- Y Combinator (participant)
- Other unnamed existing investors (participant)
Investors in our directory
Funds linked from Probably Genetic's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Potential differentiation depends on structured patient information, consistent provenance and repeat institutional use. Dataset scale alone does not establish a defensible research advantage.
Diligence should distinguish profiles, completed tests and research-ready longitudinal records, while measuring partner renewals and delivery costs. Patient-access and research budgets should not be assumed to have identical economics.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Probably Genetic's financing or category context.
FAQs about Probably Genetic
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.